-
Something wrong with this record ?
Phosphonate-titanium dioxide assemblies: platform for multimodal diagnostic-therapeutic nanoprobes
I. Řehoř, V. Vilímová, P. Jendelová, V. Kubíček, D. Jirák, V. Herynek, M. Kapcalová, J. Kotek, J. Černý, P. Hermann, I. Lukeš,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21662977
DOI
10.1021/jm200449y
Knihovny.cz E-resources
- MeSH
- Affinity Labels chemical synthesis chemistry pharmacology MeSH
- Fluorescent Dyes chemical synthesis chemistry pharmacology MeSH
- Microscopy, Fluorescence MeSH
- Gadolinium MeSH
- HeLa Cells MeSH
- Coordination Complexes chemical synthesis chemistry pharmacology MeSH
- Phosphorous Acids chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Mesenchymal Stem Cells metabolism MeSH
- Mice MeSH
- Nanoparticles MeSH
- Antineoplastic Agents chemical synthesis chemistry pharmacology MeSH
- Drug Screening Assays, Antitumor MeSH
- T-Lymphocytes metabolism MeSH
- Titanium chemistry pharmacology MeSH
- Ultraviolet Rays MeSH
- Cell Survival drug effects MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Multimodal imaging-therapeutic nanoprobe TiO(2)@RhdGd was prepared and successfully used for in vitro and in vivo cell tracking as well as for killing of cancer cells in vitro. TiO(2) nanoparticles were used as a core for phosphonic acid modified functionalities, responsible for contrast in MRI and optical imaging. The probe shows high (1)H relaxivity and relaxivity density values. Presence of fluorescent dye allows for visualization by means of fluorescence microscopy. The applicability of the probe was studied, using mesenchymal stem cells, cancer HeLa cells, and T-lymphocytes. The probe did not exhibit toxicity in any of these systems. Labeled cells were successfully visualized in vitro by means of fluorescence microscopy and MRI. Furthermore, it was shown that the probe TiO(2)@RhdGd can be changed into a cancer cell killer upon UV light irradiation. The above stated results represent a valuable proof of a principle showing applicability of the probe design for diagnosis and therapy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12028261
- 003
- CZ-PrNML
- 005
- 20130201091357.0
- 007
- ta
- 008
- 120817e20110705xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1021/jm200449y $2 doi
- 035 __
- $a (PubMed)21662977
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Řehoř, Ivan $u Department of Inorganic Chemistry, Faculty of Science, Charles University in Prague, Hlavova 2030, 128 40 Prague 2, Czech Republic.
- 245 10
- $a Phosphonate-titanium dioxide assemblies: platform for multimodal diagnostic-therapeutic nanoprobes / $c I. Řehoř, V. Vilímová, P. Jendelová, V. Kubíček, D. Jirák, V. Herynek, M. Kapcalová, J. Kotek, J. Černý, P. Hermann, I. Lukeš,
- 520 9_
- $a Multimodal imaging-therapeutic nanoprobe TiO(2)@RhdGd was prepared and successfully used for in vitro and in vivo cell tracking as well as for killing of cancer cells in vitro. TiO(2) nanoparticles were used as a core for phosphonic acid modified functionalities, responsible for contrast in MRI and optical imaging. The probe shows high (1)H relaxivity and relaxivity density values. Presence of fluorescent dye allows for visualization by means of fluorescence microscopy. The applicability of the probe was studied, using mesenchymal stem cells, cancer HeLa cells, and T-lymphocytes. The probe did not exhibit toxicity in any of these systems. Labeled cells were successfully visualized in vitro by means of fluorescence microscopy and MRI. Furthermore, it was shown that the probe TiO(2)@RhdGd can be changed into a cancer cell killer upon UV light irradiation. The above stated results represent a valuable proof of a principle showing applicability of the probe design for diagnosis and therapy.
- 650 _2
- $a afinitní značky $x chemická syntéza $x chemie $x farmakologie $7 D000345
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a komplexní sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D056831
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a fluorescenční barviva $x chemická syntéza $x chemie $x farmakologie $7 D005456
- 650 _2
- $a gadolinium $7 D005682
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 650 _2
- $a mezenchymální kmenové buňky $x metabolismus $7 D059630
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a fluorescenční mikroskopie $7 D008856
- 650 _2
- $a nanočástice $7 D053758
- 650 _2
- $a kyseliny fosforité $x chemická syntéza $x chemie $x farmakologie $7 D010757
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a T-lymfocyty $x metabolismus $7 D013601
- 650 _2
- $a titan $x chemie $x farmakologie $7 D014025
- 650 _2
- $a ultrafialové záření $7 D014466
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vilímová, Vanda
- 700 1_
- $a Jendelová, Pavla
- 700 1_
- $a Kubíček, Vojtěch
- 700 1_
- $a Jirák, Daniel
- 700 1_
- $a Herynek, Vít
- 700 1_
- $a Kapcalová, Miroslava
- 700 1_
- $a Kotek, Jan
- 700 1_
- $a Černý, Jan
- 700 1_
- $a Hermann, Petr
- 700 1_
- $a Lukeš, Ivan
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 54, č. 14 (20110705), s. 5185-94
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21662977 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20130201091525 $b ABA008
- 999 __
- $a ok $b bmc $g 950303 $s 785607
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 54 $c 14 $d 5185-94 $e 20110705 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20120817/11/04